Interleukin-6 inhibitors are emerging as potential therapeutic agents in ACS due to IL-6′s central role in propagating inflammation, activating leukocytes and adipose tissue to amplify inflammation, stimulating hepatic production of hs-CRP (a biomarker of cardiovascular risk), promoting endothelial dysfunction, plaque instability, and adverse remodeling post-ACS [196]. Here, IL6 is linked to endothelial dysfunction.